Company intelligence / Profile preview

Acumen Pharmaceuticals, Inc.

Newton, Massachusetts, United Statesacumenpharm.com ↗

Ownership: Public · ABOS
Development stage: Phase 1

Overview

Acumen is currently conducting the Phase 2 ALTITUDE-AD clinical trial of sabirnetug (ACU193) in early symptomatic Alzheimer's disease patients. They recently completed a Phase 1 study of a subcutaneous formulation of sabirnetug in healthy volunteers, which showed the formulation was well-tolerated with sufficient systemic exposure to support further clinical development. The company previously completed the Phase 1 INTERCEPT-AD trial with positive results.

Therapeutic areas: Neurology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

4 assets

sabirnetug

3 more assets in the full pipeline.

Request access →

Financials

Market cap: $205.8M
Total revenue: $0
Enterprise value: $127.3M

Beyond the preview

Go deeper on Acumen Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acumen Pharmaceuticals, Inc..

Explore the full profile